Chicago Capital Reduces Stake in PROCEPT BioRobotics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- Stake Reduction Details: Chicago Capital disclosed a reduction of 377,850 shares in PROCEPT BioRobotics during Q4, translating to an estimated $12.53 million trade, indicating a potential loss of confidence as the remaining stake is valued at $37.47 million.
- Ownership Percentage Shift: Following the sale, Chicago Capital's stake in PROCEPT decreased from 1.38% to 0.93%, reflecting a diminished focus on the company within its portfolio, which may impact market sentiment towards the stock.
- Company Financial Performance: Despite PROCEPT achieving a 43% revenue increase in Q3 to $83.3 million, its stock has plummeted over 60% in the past year, raising concerns about its ability to achieve sustainable profitability amidst ongoing operating losses.
- Future Outlook: Management has projected revenue for 2026 to be between $410 million and $430 million, implying up to 32% growth from 2025 levels, yet high operational losses and spending remain critical concerns for investors.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PRCT with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on PRCT
Wall Street analysts forecast PRCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRCT is 51.75 USD with a low forecast of 38.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 29.120
Low
38.00
Averages
51.75
High
65.00
Current: 29.120
Low
38.00
Averages
51.75
High
65.00
About PRCT
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chicago Capital Reduces Stake in PROCEPT BioRobotics
- Stake Reduction Details: Chicago Capital disclosed a reduction of 377,850 shares in PROCEPT BioRobotics during Q4, translating to an estimated $12.53 million trade, indicating a potential loss of confidence as the remaining stake is valued at $37.47 million.
- Ownership Percentage Shift: Following the sale, Chicago Capital's stake in PROCEPT decreased from 1.38% to 0.93%, reflecting a diminished focus on the company within its portfolio, which may impact market sentiment towards the stock.
- Company Financial Performance: Despite PROCEPT achieving a 43% revenue increase in Q3 to $83.3 million, its stock has plummeted over 60% in the past year, raising concerns about its ability to achieve sustainable profitability amidst ongoing operating losses.
- Future Outlook: Management has projected revenue for 2026 to be between $410 million and $430 million, implying up to 32% growth from 2025 levels, yet high operational losses and spending remain critical concerns for investors.
Continue Reading
Chicago Capital Reduces PRCT Stake
- Share Reduction Details: Chicago Capital sold 377,850 shares of PRCT in Q4, with an estimated transaction value of $12.53 million, indicating a decrease in confidence towards the stock.
- Position Value Decline: As of December 31, the value of Chicago Capital's PRCT holdings was $37.47 million, down $18.52 million from the previous quarter, reflecting the dual impact of trading activities and stock price movements.
- Market Performance Comparison: PRCT's stock price has plummeted 60.4% over the past year, significantly underperforming the S&P 500's approximately 14% gain, highlighting market concerns regarding its future profitability.
- Growth Potential vs. Risks: Despite a 43% year-over-year revenue increase to $83.3 million in Q3 and management's revenue guidance of $410 million to $430 million for 2026, ongoing operating losses and high expenditures raise doubts about sustainable profitability, affecting investor sentiment.
Continue Reading